$JAZZ SEC Filings

Estimated Q3 Financial Impacts Related to the Actio Biosciences, Inc. Acquisition

On October 6, 2026, Samantha Pearce, Executive Vice President, Chief Commercial Officer of Jazz Pharmaceuticals plc (the “Company”), notified the Company of her intent to retire from her role as Chief Commercial Officer upon the earlier ...

Sold 2,000 shares ($473K)

Sold 6,000 shares ($1.38M)

This AMENDMENT No. 4, dated as of September 23, 2026 (this “Amendment”), to the Credit Agreement, dated as of May 5, 2021 (as amended by that certain LIBOR Successor Rate Conforming Changes Amendment, dated as of June 7, 2023, that certa...

Acquisition adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1-related epilepsy

Sold 1,200 shares ($289K)

Gave up 1,427 shares to cover exercise price or tax ($347K)

Gave up 1,967 shares to cover exercise price or tax ($485K) · Sold 2,000 shares ($486K)

Gave up 2,092 shares to cover exercise price or tax ($505K)

Gave up 1,706 shares to cover exercise price or tax ($412K)

Gave up 1,706 shares to cover exercise price or tax ($412K)

Gave up 743 shares to cover exercise price or tax ($179K)

Gave up 1,706 shares to cover exercise price or tax ($412K)